Trial reportPsychological medicine2024
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.
Trial report in Psychological medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review.JAMA network open · 2026Pooled it
- Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience.Journal of psychopharmacology (Oxford, England) · 2026Trial
- LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.The British journal of psychiatry : the journal of mental science · 2024Trial
- Natural medicine‑empowered treatment of depression via restoring neurogenesis (Review).Molecular medicine reports · 2026Review
- Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review.International journal of molecular sciences · 2026Article
- Case Report: Amplified psychoanalysis? Psychoanalysis, OCD and MDMA in a clinical case study.Frontiers in psychology · 2026Article
- The experiential self state as affective salience: a dual-self states framework for consciousness and self-transcendence.Neuroscience of consciousness · 2026Article
- Development and psychometric evaluation of the Oneness Experience Scale.Frontiers in psychology · 2026Article
- Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?Dialogues in clinical neuroscience · 2025Review
- Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.CNS drugs · 2025Review
- Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings.Scientific reports · 2025Article
- From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.Pharmacology research & perspectives · 2025Review
- An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers.Neuroscience applied · 2025Article
- Brain neural mechanisms underlying VR enhanced aerobic exercise for mood enhancement in depressed adolescents.Frontiers in human neuroscience · 2025Article
- A Critical View on New and Future Antidepressants.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Review
- Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor.iScience · 2024Article
- Psilocybin for the treatment of Alzheimer's disease.Frontiers in neuroscience · 2024Review
- Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome.Journal of clinical gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundPsilocybin Therapy (PT) is being increasingly studied as a psychiatric intervention. Personality relates to mental health and can be used to probe the nature of PT's therapeutic action.
methodsIn a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, over a core 6-week trial period. Five-Factor model personality domains, Big Five Aspect Scale Openness aspects, Absorption, and Impulsivity were measured at Baseline, Week 6, and Month 6 follow-up.
resultsPT was associated with decreases in neuroticism (
conclusionsPersonality changes across both conditions were in a direction consistent with improved mental health. With the possible exception of trait absorption, there were no compelling between-condition differences warranting conclusions regarding a selective action of PT (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.